A new study in the UK will investigate the long-term effects of lung inflammation and scarring from COVID-19, Imperial College London announced on Wednesday.
After battling COVID-19, many patients experience long-term symptoms of lung damage, including breathlessness, coughing, fatigue and limited ability to exercise.
The inflammation in the lungs may improve over time, but in some people it persists and in severe cases the lungs may become scarred, Imperial explained.
Supported by GBP2m of funding from UK Research and Innovation (UKRI), the researchers at Imperial aim to develop treatment strategies to prevent the development of severe scarring and disability following COVID-19.
(USD1=GBP0.73)
Celltrion launches AVTOZMA IV in the United States following FDA approval
Novartis to launch US direct-to-patient platform for Cosentyx
Vascarta completes VAS-101 osteoarthritis clinical trial
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University
ResVita Bio completes face-to-face Pre-IND meeting with FDA for RVB-003
N4 Pharma advances RNA delivery breakthrough with SRI collaboration
EMA recommends marketing approval of Alvotech's Gobivaz biosimilar to Simponi
Evommune reveals further positive data from Phase 2 EVO756 trial
J & D Pharmaceuticals receives Orphan Drug Designation for JD-004
Ascletis presents Phase III results of denifanstat (ASC40) for acne treatment at EADV Congress 2025
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa